University of Florida Center for Movement Disorders & Neurorestoration, Department of Neurology, 3450 Hull Road Gainesville, FL 32607, USA.
Toxins (Basel). 2012 Nov 7;4(11):1196-222. doi: 10.3390/toxins4111196.
Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity. These syndromes have typically been associated with abnormalities in cholinergic transmission. Despite the multiplicity of botulinal serotypes (designated as types A through G), therapeutic preparations are currently only available for BoNT types A and B. However, other BoNT serotypes are under study for possible clinical use and new clinical indications;
To review the current research on botulinum neurotoxin serotypes A-G, and to analyze potential applications within basic science and clinical settings;
The increasing understanding of botulinal neurotoxin pathophysiology, including the neurotoxin's effects on specific neuronal populations, will help us in tailoring treatments for specific diagnoses, symptoms and patients. Scientists and clinicians should be aware of the full range of available data involving neurotoxin subtypes A-G.
二十年前，A型肉毒毒素（BoNT）被引入商业市场。随后，该毒素被 FDA 批准用于治疗多种涉及肌肉、神经和腺体过度活跃的神经系统综合征。这些综合征通常与胆碱能传递异常有关。尽管存在多种肉毒梭菌血清型（指定为 A 至 G 型），但目前仅可获得用于 A 型和 B 型 BoNT 的治疗制剂。然而，其他 BoNT 血清型正在研究中，以寻求可能的临床应用和新的临床适应证；
综述目前关于 A-G 型肉毒神经毒素的研究，并分析其在基础科学和临床环境中的潜在应用；
对肉毒梭菌神经毒素病理生理学的认识不断增加，包括神经毒素对特定神经元群体的影响，将有助于我们针对特定诊断、症状和患者进行个体化治疗。科学家和临床医生应了解涉及神经毒素亚型 A-G 的所有可用数据。
Zotero 插件
